Subscribe To

Price Alert Latest News Economic Calendar News

GRCL / Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress

First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety profile for treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Longer-term GC012F data in relapsed/refractory multiple myeloma (RRMM) and B-cell non-Hodgkin's lymphoma (B-NHL) indications to be highlighted, with B-NHL data selected for oral presentation SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , May 11, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online. Read More

Demo Live Account See Partner Details

Content Topics

Gracell

Biotechnologies

Present

Clinical

Data

Bcma

Cd19

Bcma cd19

Dual targeting

Fastcar t

Gc012f

Donor derived

Gc007g

Eha2023

Congress

Stock

GRCL

Posted: May 11 2023, 17:28

Author Name: PRNewsWire

GRCL News

By GlobeNewsWire
November 1, 2023

Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDA

By GlobeNewsWire
September 14, 2023

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a gl

By GlobeNewsWire
August 24, 2023

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob

By Seeking Alpha
August 14, 2023

Gracell Biotechnologies Inc. (GRCL) Q2 2023 Earnings Call Transcript

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants William Cao - Chairman, C

By The Motley Fool
August 7, 2023

Why Shares of Gracell Biotechnologies Are Rising Monday

Gracell Biotechnologies is a clinical-stage biotech company based in China. The company's lead therapy is in four different trials to treat various di

By GlobeNewsWire
July 31, 2023

Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023

SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob

By Zacks Investment Research
June 14, 2023

Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why

Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug

By The Motley Fool
June 13, 2023

Why Shares of Gracell Biotechnologies Jumped Tuesday

Two analysts upgraded their ratings for Gracell Biotechnologies' stock. Over the weekend, Gracell announced positive follow-up trial data regarding it

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.